A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Running, not enrolling · Phase 3 · Has a placebo group
Conditions studied: Hidradenitis Suppurativa
In brief
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
Key facts
- Study ID
- NCT06840392
- Run by
- Novartis Pharmaceuticals
- People needed
- 565
- Starts
- 2025-03-20
- Expected to finish
- 2027-10-21
- Last updated by the study team
- 2026-06-05
Who can join
Age: 12 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- CTT Research — Gilbert, Arizona, United States
- Ctr Dermatology and Plastic Surgery — Scottsdale, Arizona, United States
- Ctr for Dermatology Clinical Res — Fremont, California, United States
- USC Keck School of Medicine — Los Angeles, California, United States
- MedDerm Associates — San Diego, California, United States
- Driven Research — Coral Gables, Florida, United States
- Floridian Research Institute — Miami, Florida, United States
- Sarasota Arthritis Res Ctr — Sarasota, Florida, United States
- University Of South Florida — Tampa, Florida, United States
- Emory School of Med Dermatology — Atlanta, Georgia, United States
- Atlanta Biomedical Clin Res LLC — Atlanta, Georgia, United States
- Northwestern University — Chicago, Illinois, United States
- Endeavor Health — Glenview, Illinois, United States
- Dundee Dermatology — West Dundee, Illinois, United States
- Southern IN Clinical Trials — New Albany, Indiana, United States
- Beth Israel Deaconess Med Center — Boston, Massachusetts, United States
- Metro Boston Clinical Partners — Brighton, Massachusetts, United States
- Clinical Research Inst of MI — Chesterfield, Michigan, United States
- Deluxe Dermatology — St Louis, Missouri, United States
- Skin Specialists PC — Omaha, Nebraska, United States
- Vivida Dermatology — Las Vegas, Nevada, United States
- North Shore University Hospital — New Hyde Park, New York, United States
- Cameron Dermatology — New York, New York, United States
- Optima Research Boardman — Boardman, Ohio, United States
- Total Skin and Beauty Dermatology Center PC — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.